Acelyrin adds proof-of-concept TED data to recent readout pile, cementing challenge to Amgen The izokibep clinical rollercoaster took off just months after Acelyrin went public in May 2023.

BioMarin revealed changes to its C-suite; now, the company has announced its second round of layoffs this year, following the termination of 170 employees in May.

The company has reshuffled its executive team, cut back spending and trimmed its drug pipeline this year, changes aimed at ...

Amgen (NASDAQ:AMGN) traded lower on Wednesday as Wells Fargo downgraded the Dow component to Equal Weight from Overweight, arguing that the stock already reflects a potential trial success for the ...

Amgen shares fell 5% Wednesday after the drug developer lowered its full-year earnings guidance. Second-quarter revenue jumped 20% year-over-year to $8.4 billion, slightly above expectations ...

As with Epogen, the initial discoveries that laid the basis for the drug had ... That decade of investment and research was paying off. In 1992, Amgen hit the billion dollars sales mark and ...

The rightsizing at BioMarin continues to take its toll as CEO Alexander Hardy devises a new corporate strategy for the rare disease biotech. | The rightsizing at BioMarin continues to take its toll as ...

The FTC said in its complaint that Amgen would be able to leverage its ... President Biden is set to lay out his vision Thursday for reducing the high cost of prescription drugs, and is expected ...

Sept 4 (Reuters) - Amgen (AMGN.O), opens new tab will test its obesity drug candidate in patients at risk of weight-related conditions such as heart, liver and kidney diseases in its late-stage ...

Speaking on a conference call Tuesday, executives at Amgen again fielded a long slate ... Precigen Therapeutics on Wednesday said it would lay off 20% of its workforce as part of a “strategic ...

ANNOUNCER: 'Think Tank' has been made possible by Amgen, arecipient of the Presidential ... you have the whole vision laid out justas it was in the 1960s. But the 1960s were a crucial point ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...